StartupsForbes Innovationabout 1 hour ago
Apnimed Raises $192M in Sleep Apnea Pill IPO
1 min read
Apnimed priced its IPO at $16 per share, raising $192 million and valuing the Cambridge, Mass. biotech above $600 million. The company's once-nightly sleep apnea pill awaits FDA approval, with a decision possible in the first quarter of 2027.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
